Patient out-of-pocket costs for cannabis use during cancer treatment DOI Creative Commons
Kaitlyn Lapen, Akriti Mishra Meza, Edward Christopher Dee

et al.

JNCI Monographs, Journal Year: 2024, Volume and Issue: 2024(66), P. 305 - 312

Published: Aug. 1, 2024

Abstract Background We assessed patient costs associated with cannabis use during cancer treatment. Methods Adults treated for at a large, comprehensive center completed an anonymous survey regarding their thoughts and experiences cancer. Bivariate weighted multivariable logistic regression clinical sociodemographic factors patient-reported out-of-pocket products. Results Overall, 248 users provided data on cost were analyzed. Median monthly was $80 (interquartile range = $25-$150). On analysis, male gender (odds ratio 2.5, 95% confidence interval 1.2 to 5.5, P .026) being 45 years of age or older 7.5, 1.9 30.0, .0042) spending $100 month more cannabis. Of the 166 patients who stopped using early used less than preferred, 28% attributed it 26% lack insurance coverage. Conclusion Cannabis treatment may contribute significant costs, men younger likely pay higher costs.

Language: Английский

Potential Anti-Tumorigenic Properties of Diverse Medicinal Plants against the Majority of Common Types of Cancer DOI Creative Commons
Ghosoon Albahri,

Adnan Badran,

Zaher Abdel Baki

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(5), P. 574 - 574

Published: April 30, 2024

Globally, cancer is one of the primary causes both morbidity and mortality. To prevent from getting worse, more targeted efficient treatment plans must be developed immediately. Recent research has demonstrated benefits natural products for several illnesses, these have played a significant role in development novel treatments whose bioactive components serve as chemotherapeutic chemo-preventive agents. Phytochemicals are naturally occurring molecules obtained plants that potential applications therapy new medications. These phytochemicals function by regulating molecular pathways connected to onset progression cancer. Among specific methods immune system control, inducing cell cycle arrest apoptosis, preventing proliferation, raising antioxidant status, inactivating carcinogens. A thorough literature review was conducted using Google Scholar, PubMed, Scopus, Patent, Patent Scope, US obtain data. provide an overview anticancer effects medicinal plants, including Annona muricata, Arctium lappa, Arum palaestinum, Cannabis sativa, Catharanthus roseus, Curcuma longa, Glycyrrhiza glabra, Hibiscus, Kalanchoe blossfeldiana, Moringa oleifera, Nerium oleander, Silybum marianum, Taraxacum officinale, Urtica dioica, Withania somnifera L., their availability, classification, active components, pharmacological activities, signaling mechanisms, side against most common types were explored.

Language: Английский

Citations

9
Characterizing Cannabidiol Use in a Breast Cancer Population DOI
Nicole Fleege,

Bradley T. Loeffler,

Kevin F. Boehnke

et al.

Clinical Breast Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

1
The impact of cannabis on immune checkpoint inhibitor therapy: a systematic review of immunomodulatory effects of cannabis in patients with and without cancer DOI

Caroline Behling-Hess,

Grant Simonson,

Talya Salz

et al.

Supportive Care in Cancer, Journal Year: 2025, Volume and Issue: 33(3)

Published: Feb. 8, 2025

Language: Английский

Citations

1
Cannabis use prevalence, patterns, and reasons for use among patients with cancer and survivors in a state without legal cannabis access DOI
Erin A. McClure, Kyle J. Walters, Rachel L. Tomko

et al.

Supportive Care in Cancer, Journal Year: 2023, Volume and Issue: 31(7)

Published: June 29, 2023

Language: Английский

Citations

22
Nutrition, endocannabinoids, and the use of cannabis: An overview for the nutrition clinician DOI Creative Commons
Lindsey Russell,

Kayla Condo,

Tiffany DeFlorville

et al.

Nutrition in Clinical Practice, Journal Year: 2024, Volume and Issue: 39(4), P. 815 - 823

Published: March 30, 2024

The endocannabinoid system (ECs) is composed of multiple signaling compounds and receptors within the central peripheral nervous along with various organs, including gut, liver, skeletal muscle. ECs has been implicated in metabolism, gut motility, eating behaviors. altered disease states such as obesity. Recent studies have clarified role microbiome nutrition on ECs. Exogenous cannabinoid (CB) use, either organic or synthetic, stimulates through CB1 CB2 receptors. However, CBs unclear regard to optimization treat states. This review briefly summarizes effect exogenous metabolism nutrition. With increased legalization cannabis, there a corresponding use United States. Therefore, clinicians need be aware both benefits harm cannabis overall status, well gaps knowledge for future research guideline development.

Language: Английский

Citations

6
Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy DOI Open Access
Mendhi Henna Dasram,

Pavesan Naidoo,

Roderick B. Walker

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(3), P. 1371 - 1371

Published: Jan. 23, 2024

The highly aggressive and invasive glioblastoma (GBM) tumour is the most malignant lesion among adult-type diffuse gliomas, representing common primary brain in neuro-oncology practice of adults. With a poor overall prognosis strong resistance to treatment, this nervous system requires new innovative treatment. GBM polymorphic consisting an array stromal cells various contributing initiation, progression, treatment response. Cannabinoids possess anti-cancer potencies against glioma cell lines animal models. To improve existing cannabinoids as functionalised ligands on nanocarriers were investigated potential agents. microenvironment multifaceted resident or recruited immune cells, extracellular matrix components, tissue-resident soluble factors. accounts for substantial volume tumours. barriers with cannabinoids, such crossing blood–brain barrier psychoactive off-target side effects, can be alleviated use nanocarrier drug delivery systems improved specificity targeting pharmacological receptors signalling pathways. This review has shown presence endocannabinoid microenvironment, which used unique target specific delivery. Existing cannabinoid agents, studied previously, show via pathways associated hallmarks cancer. results provide guidance design future therapy

Language: Английский

Citations

5
Review of the Use of Medicinal Cannabis Products in Palliative Care DOI Open Access

James Troyer,

Kimberson Tanco

Cancers, Journal Year: 2024, Volume and Issue: 16(7), P. 1412 - 1412

Published: April 4, 2024

In this review, we discuss the potential role of cannabis and cannabinoids in management cancer-related symptoms. There is limited evidence demonstrating effectiveness cannabis-based products treating pain gastrointestinal symptoms such as nausea, vomiting, loss appetite. Regarding treatment insomnia mood disorders, most studies looked at these secondary outcomes with mixed results. Cannabis-based have adverse effects, ranging from neuropsychiatric to systemic effects drug interactions.

Language: Английский

Citations

5
Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts DOI Creative Commons
Gérard Mick,

Pascal Douek

Pain and Therapy, Journal Year: 2024, Volume and Issue: 13(5), P. 1063 - 1094

Published: Aug. 3, 2024

Interest in medical cannabis and cannabis-based medicinal products (CBMPs) has increased greatly recent years. Two cannabinoids are of principal importance; delta-9-tetrahydrocannabinol (∆9-THC), the primary psychoactive component, also cannabidiol (CBD), considered non-intoxicating. Each distinct mechanisms action different therapeutic potentials. CBMPs differ their ∆9-THC CBD components; predominantly ∆9-THC, balanced formulations with equivalent elements, CBD-predominant products. In this narrative review, we evaluate published evidence for clinical benefits overall well-being. We review safety profile discuss potential dependence CBMPs. Evidence can be drawn from a wide range randomized other controlled studies observational real-world studies. Most data registry supportive ∆9-THC-based (∆9-THC-predominant or CBMPs) management chronic neuropathic pain. Balanced effective reducing spasticity multiple sclerosis. show benefit providing symptomatic anxiety, nausea, improving sleep, but place specific is more subtle, choice guided by circumstances. Symptomatic improvements accompanied improved quality life Safety indicate that generally well tolerated most patients without contraindications. The majority adverse effects non-serious, transient; principally associated dose-dependent. contrast to recreational use, there little have any dependence.

Language: Английский

Citations

4
Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer DOI Creative Commons
Theodore M. Brasky, Alison M. Newton, Sara Conroy

et al.

Cancer Research Communications, Journal Year: 2023, Volume and Issue: 3(9), P. 1917 - 1926

Published: Sept. 11, 2023

Symptoms such as pain, nausea, and anxiety are common in individuals with cancer. Treatment of these issues is often challenging. Cannabis products may be helpful reducing the severity symptoms. While some studies include data on prevalence cannabis use among patients cancer, detailed remain limited, none have reported cannabidiol (CBD) this population. Adult cancer attending eight clinics at a large, NCI-designated Comprehensive Cancer Center completed detailed, cannabis-focused questionnaire between 2021 2022. Eligible participants were diagnosed invasive treated past 12 months. Summary statistics calculated to describe sample regarding use. Approximately 15% (n = 142) consented 934) current (defined within months). Among which, 75% week. users, 39% 56; 6% overall) used CBD products. Current users using median 4.5 (interquartile range: 0.6–7.0) days/week, 2.0 (1.0–3.0) times per use/day, for 3 years (0.8–30.0). Use patterns varied by route administration. Patients moderate high relief symptoms This study most date terms measurement provides information about state active Future should complete assessments product use, multiple recruitment sites, diverse patient populations.

Language: Английский

Citations

10
Cannabis Use and Disclosure in the Oncology Setting: A Cross-Sectional Survey Exploring Information Needs Among Cancer Survivors DOI Open Access
Lily Camp,

Viktoriya Babicheva,

Catherine Conahan

et al.

Clinical journal of oncology nursing, Journal Year: 2025, Volume and Issue: 29(2), P. 157 - 164

Published: March 14, 2025

Background: Given the potential positive and negative impacts of cannabis use during cancer care, more information is needed to understand how changes in legalization social norms have affected clinical disclosure among survivors.Objectives: The purpose this research was explore behaviors, disclosure, needs survivors.Methods: study team conducted cross- sectional analyses using descriptive statistics assess data collected via an online survey distributed through health communities.Findings: This analysis included 719 participants, most reported currently undergoing treatment. About one-third current use. Cannabis varied across care continuum, those discussed their with a healthcare provider interest receiving about cannabis.

Language: Английский

Citations

0